Replacement of Genetic Testing

I have been diagnosed with lung cancer. I am worried by having to wait so long for my diagnosis and treatment. Is there any way to speed this up?

Regular Process

Cancer diagnoses, such as in lung cancer, can be followed by tumor genetic testing. This enables doctors to tailor treatment more effectively for their patients. However, these tests are costly and time consuming and are not always reliable since the genetic material (DNA) extracted from the tumor is not consistently suitable for testing. 4D Path is developing a solution to overcome this problem by using an algorithm to identify features based on the appearance of the tumor that reflect the underlying genetic abnormalities. This promises to deliver a cheaper and faster diagnostic/treatment pathway, which does not depend on DNA testing.

  • Visual/Process/Subsite/26Created with Sketch.
    01
    Diagnose cancer type
  • Visual/Process/Subsite/27Created with Sketch.
    02
    Genetic material extracted from tumor
  • Visual/Process/Subsite/04Created with Sketch.
    03
    Report about genetic abnormalities
  • Visual/Process/Subsite/09Created with Sketch.
    04
    Tailored treatment

4D Path Process

4D Path is developing a solution to overcome this problem by using an algorithm to identify features based on the appearance of the tumor that reflect the underlying genetic abnormalities. This promises to deliver a cheaper and faster diagnostic/treatment pathway, which does not depend on DNA testing.

Automated
  • Visual/Process/Subsite/26Created with Sketch.
    01
    Identified tumor cell
  • Visual/Process/Subsite/28Created with Sketch.
    02
    Automated finding of morphological features
  • Visual/Process/Subsite/04Created with Sketch.
    03
    Report about genetic abnormalities
  • Visual/Process/Subsite/09Created with Sketch.
    04
    Tailored treatment
Cancer diagnoses are often followed by supplementary investigations such as genetic testing. In lung cancer, ALK, EGFR and Ros-1 status are typically assessed. In malignant melanoma, the focus lies instead on BRAF and NRAS mutations. These tests are costly and require good quality DNA and sufficient tumor representation, which is not always reliably obtained from formalin-fixed tissue and/or biopsies. 4D Path is developing an automated diagnostic solution that reflects the spectrum of underlying mutations in tumors that otherwise look identical to the human eye. The results of this approach will be a cost-effective, treatment-focused approach to patient management whilst obviating the need for genetic testing.